Healthcare investment fund Gurnet Point said today that it completed its acquisition of pharmaceutical and medical device company Innocoll.
According to the deal, Gurnet Point is slated to buy Innocoll for 1.75 per share in cash and up to $4.90 in cash from a contingent value right, in a deal valued up to $209 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Healthcare fund Gurnet Point buys Innocoll’s bioresorbable collagen matrix appeared first on MassDevice.